Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 252

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial

Open access
Selim, Magdy, Foster, Lydia D, Moy, Claudia S, Xi, Guohua, Hill, Michael D, Morgenstern, Lewis B, Greenberg, Steven M, James, Michael L, Singh, Vineeta, Clark, Wayne M, Norton, Casey, Palesch, Yuko Y, Yeatts, Sharon D, Dolan, Monica, Yeh, Erlinda, Sheth, Kevin, Kunze, Kimberly, Muehlschlegel, Susanne, Nieto, Iryna, Claassen, Jan, Falo, Cristina, Huang, David, Beckwith, Anne, Messe, Steven, Yates, Melissa, O'Phelan, Kristine, Escobar, Andrea, Becker, Kyra, Tanzi, Patricia, Gonzales, Nicole, Tremont, Chad, Venkatasubramanian, Chitra, Thiessen, Rosita, Save, Supriya, Verrault, Steven, Collard, Karin, DeGeorgia, Michael, Cwiklinski, Valerie, Thompson, Bradford, Wasilewski, Lesley, Andrews, Charles, Burfeind, Robert, Torbey, Michel, Hamed, Mohammad, Butcher, Kenneth, Sivakumar, Leka, Varelas, Nicolaou, Mays-Wilson, Kathleen, Leira, Enrique, Olalde, Heena, Silliman, Scott, Calhoun, Rhonda, Dangayach, Neha, Renvill, Ricardo, Malhotra, Rishi, Kordesch, Kristina, Lord, Aaron, Calahan, Thomas, Geocadin, Romergryko, Parish, Michelle, Frey, James, Harrigan, Mary, Leifer, Dana, Mathias, Ryna, Schneck, Michael, Bernier, Tara, Gonzales-Arias, Sergio, Elysee, Josette, Lopez, George, Volgi, Josephine, Brown, Robert, Jasak, Sara, Phillips, Stephen, Jarrett, Judith, Gomes, Joao, McBride, Moneen, Aldrich, Francois, Aldrich, Charlene, Kornbluth, Joshua, Bettle, Michelle, Goldstein, Joshua, Tirrell, Gregory, Shaw, Qaisar, Jonczak, Karin · 2019 · The Lancet Neurology

Abstract

SUMMARY Background: Iron, from hemolyzed blood, is implicated in secondary injury after intracerebral haemorrhage (ICH). We aimed to evaluate the safety of the iron chelator, Deferoxamine Mesylate (DFO), and whether it merits investigation in a Phase-III study to definitively assess its effectiveness in improving outcomes in ICH patients. Methods: We conducted a multi-center, randomised, double-blind, placebo-controlled, Phase-II trial at 40 hospitals in USA and Canada. Adults (aged 18–80 years) with primary, spontaneous, supratentorial ICH were randomly assigned (1:1) to DFO (32 mg/kg/day) or saline (placebo) infusions for 3 consecutive days, within 24-hours of ICH-onset. Randomisation was done centrally in real-time and treatment allocation was concealed from participants and investigators. Primary outcome was good clinical outcome, defined as modified Rankin Scale (mRS) score 0–2 at day-90. We performed a futility analysis; if the 90% upper confidence bound (90%UCB) on the absolute risk difference in good outcome proportions is <12% in favour of DFO, then it would be futile to move to Phase-III. Outcome and safety data were analysed based on modified intention-to-treat. (ClinicalTrials.gov Identifier:NCT02175225). Findings: We recruited 294 participants between November 23, 2014 and November 10, 2017. Three were post-randomisation failure; 291 were included in the analyses (144 randomised to DFO; 147 to placebo). Primary outcome was assessed for 283 (97.3%) participants. At day-90, 48/140 (34.3%) of DFO- and 47/143 (32.9%) of placebo-treated subjects had mRS 0–2 (adjusted absolute risk difference 0.6%; 90%UCB 6.8%). By day-90, 70 serious adverse events were reported in 39/144 (27.1%) DFO group and 78 in 49/174 (33.3%) placebo-treated subjects. Death occurred in 10 (6.9%) DFO- and 11 (7.5%) placebo-subjects; none was treatment-related. Interpretation: DFO was safe. The primary result showed it would be futile to further study the effectiveness of DFO with anticipation that it would significantly improve the chance of good outcome (mRS 0–2) at day-90.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(19)30069-9

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 252

Metadata

Authors
Selim, M., Foster, L. D., Moy, C. S., Xi, G., Hill, M. D., Morgenstern, L. B., Greenberg, S. M., James, M. L., Singh, V., Clark, W. M., Norton, C., Palesch, Y. Y., Yeatts, S. D., Dolan, M., Yeh, E., Sheth, K., Kunze, K., Muehlschlegel, S., Nieto, I., Claassen, J., Falo, C., Huang, D., Beckwith, A., Messe, S., Yates, M., O'Phelan, K., Escobar, A., Becker, K., Tanzi, P., Gonzales, N., Tremont, C., Venkatasubramanian, C., Thiessen, R., Save, S., Verrault, S., Collard, K., DeGeorgia, M., Cwiklinski, V., Thompson, B., Wasilewski, L., Andrews, C., Burfeind, R., Torbey, M., Hamed, M., Butcher, K., Sivakumar, L., Varelas, N., Mays-Wilson, K., Leira, E., Olalde, H., Silliman, S., Calhoun, R., Dangayach, N., Renvill, R., Malhotra, R., Kordesch, K., Lord, A., Calahan, T., Geocadin, R., Parish, M., Frey, J., Harrigan, M., Leifer, D., Mathias, R., Schneck, M., Bernier, T., Gonzales-Arias, S., Elysee, J., Lopez, G., Volgi, J., Brown, R., Jasak, S., Phillips, S., Jarrett, J., Gomes, J., McBride, M., Aldrich, F., Aldrich, C., Kornbluth, J., Bettle, M., Goldstein, J., Tirrell, G., Shaw, Q., & Jonczak, K.
Venue
The Lancet Neurology
Publisher
Elsevier BV
Published
2019-05
Volume
18
Issue
5
Pages
428-438
ISSN
1474-4422 (ISSN-L)
OpenAlex
W2921259698
Cited by
252
References
1
FWCI
18.00
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. https://app.cochat.ai/papers/10.1016/s1474-4422(19)30069-9
The paper
Selim, M., Foster, L. D., Moy, C. S., Xi, G., Hill, M. D., Morgenstern, L. B., Greenberg, S. M., James, M. L., Singh, V., Clark, W. M., Norton, C., Palesch, Y. Y., Yeatts, S. D., Dolan, M., Yeh, E., Sheth, K., Kunze, K., Muehlschlegel, S., Nieto, I., . . . Jonczak, K. (2019). Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(19)30069-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.